In the Field - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

In the Field

Pharmaceutical Technology

The labeling change encourages healthcare providers to use genetic tests before prescribing warfarin. The agency believes the tests would help physicians better determine the reasonable warfarin dose for individual patients, optimize the use of warfarin, and lower the risk of bleeding complications from the drug. The labeling changes result from an analysis of recent studies that found that certain genetic variations influence the way people respond to the drug.

"Today's approved labeling change is one step in our commitment to personalized medicine. By using modern science to get the right drug in the right dose for the right patient, FDA will further enhance the safety and effectiveness of the medicines Americans depend on," FDA Commissioner Andrew C. von Eschenbach said in an agency press release. The agency's personalized medicine initiative is based on pharmacogenomics, the science that predicts a response to drugs based upon a person's genetic makeup. –Erik Greb


Working Group Releases Strategy to Ensure Import Safety

The US Food and Drug Administration's Interagency Working Group on Import Safety released a Strategic Framework on Sept. 10, based on a cost-effective, risk-based approach for ensuring the safety of products exported to the United States. Instead of assessing products at the border, the strategy recommends examining products' entire life cycles. The strategy requires cooperation with foreign manufacturers to identify and mitigate risk during crucial parts of the production and distribution process.

The Strategic Framework follows several months of scandals involving contaminated products manufactured in China. The problems prompted the US government to send a fact-finding team to China to address concerns about food and drug safety.

The Working Group aims to achieve continuous improvement in import safety by using the following six building blocks:

  • Advance a common vision
  • Increase accountability, enforcement, and deterrence
  • Focus on risk over the life cycle of an imported product
  • Build interoperable systems
  • Foster a culture of collaboration
  • Promote technological innovation and new science.

The building blocks recommend changes to the oversight process, including shared goals among federal agencies that promote import safety, better communication between parties in the global supply chain, and collaboration between government and industry.

The Framework says FDA has made 34 confidential arrangements with agencies in 17 countries to share approval, inspection, adverse-event, and emergency information about products manufactured in a partners' territories. FDA currently has more than two such exchanges each day.

In a public statement, FDA Commissioner Andrew von Eschenbach strongly endorsed the Strategic Framework, commending Health and Human Services Secretary Michael Leavitt for leading the Working Group and developing the Framework. President Bush established the Working Group in July to develop better ways to work with importers, manufacturers, and other governments to ensure the safety of imported products. -Erik Greb


FDA Proposes Study of DTC Advertising

The US Food and Drug Administration is seeking public comments on a study designed to investigate the impact of visual distraction and the interplay of different sensory modalities (e.g., verbal, visual) used to present risk and benefit information during a television prescription-drug advertisement. Data from this study will provide useful information to help improve how broadcast ads present a prescription drug's risks and benefits. Notice of the study was published in Federal Register 72 (162), 47051–47053 on Aug. 22.

The purpose of the proposed study is, in part, to determine whether the use of competing, compelling visual information about potential drug benefits interferes with viewers' processing and comprehension of risk information about drugs in direct-to-consumer (DTC) advertising or with their cognitive representations of the drugs, according to the notice. "Positive visual images could influence the processing of risk-related information and the final representation of the advertised drug in multiple ways," says the notice.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here